Anaemias and other Pesky Haematology Questions
|
|
- Susanna Murphy
- 5 years ago
- Views:
Transcription
1 Anaemias and other Pesky Haematology Questions
2 3 main topics How do I work out an anaemia.. That oh too common paraprotein patient. Those mildly raised lymphocyte count
3 GP discussed patient with me over weekend 83 yr female. Hb 103g/L. Stable level for previous 2 years MCV= 100. Plats/neuts = N Asymptomatic though previous recent TIAs
4 FIRST QUESTION IS THERE DECREASED PRODUCTION with LOW numbers of RETICULOCYTES OR INCREASED DESTRUCTION with INCREASE in RETICULOCYTES (as long as the necessary building blocks are present)
5 Increased retics= increase RBC destruction 1. Acute bleed with sufficient iron stores Or 2. Haemolytic anaemia Relatively rare Most will be referred for further work up
6 DECREASED PRODUCTION=Decreased reticulocytes 1. Lack of nutrients 2. Inflammatory process 3. Hormonal causes including lack of erythropoietin -i.e. renal impairment. Hypothyroid= relatively rare cause 4. Malproduction of haemopoietic cells i.e. myelodysplasia 5. Infiltration of bone marrow by a)fibrosis or b) malignancy
7 Our patient = Low reticulocytes- decreased production 1. Lack of nutrients? B12/folate =N (also ferritin= N) 2. Inflammatory process? CRP =N 3. Hormonal causes including lack of erythropoietin -i.e. renal impairment? Creatinine µmol/l. May be contributing a bit towards the Anaemia. Thyroid function normal.
8 DECREASED PRODUCTION=Decreased reticulocytes continued 4. Malproduction of haemopoietic cells i.e. myelodysplasia Most important test= BLOOD FILM Variation in size and shape of the red cells Hypo granulation of neutrophils May have reduction in neutrophils and platelets Q
9 5. Infiltration of bone marrow by a)fibrosis or b) malignancy BLOOD FILM very helpful Fibrosis associated with TEARDROPS and LEUKOERYTHROBLASTIC picture Needs bone marrow examination
10 5. Infiltration of bone marrow by b) malignancy Stable over last 2 years therefore unlikely to be aggressive malignancy Blood film again gave the clue Rouleaux Occurs when there is increased immunoglobulins from infection or paraprotein
11 Serum Electrophoresis showed IgM paraprotein of 25g/L If you had one test in this lady what would you do to maximise her management? 1. Bone marrow as she probably has myeloma 2. Serum viscosity as the IgM may increasing her risk of TIAs 3. A Serum Free Light Chain level 4. Bence Jones Protein
12
13 Ig M paraprotein in an otherwise asymptomatic patient with stable bloods IgM paraproteins MGUS rarely become myeloma usually low grade NHL MUST ask about night sweats/wt. loss/infections at EACH visit and tell them to report these MUST look for LN/L/S/abdominal masses at EACH visit
14 Low Grade NHL No definite benefit of early treatment ( at any age) of a LG NHL If very high IgM, once off plasma viscosity. Viscosity > 4 significant
15 Keeping to the theme of patients with paraproteins..
16 65 year woman steps awkwardly off a small stool Very significant thoracic pain X-ray showed some old looking thoracic fractures -?skiing accidents Prescribed slow release oxycodone by orthopaedic reg Still taking oxycodone 4 weeks later and significant pain
17 1 month later still taking oxycodone Bloods show normal full blood count, standard biochemistry and Total Ig G of 12 g/l (7-14) with a paraprotein present Normal IgM/A Kappa free light chain=86 mg/l ( ) Lambda free light chain = 63mg/L ( ) with a kappa/lambda ratio of 0.3mg/L ( )
18 What would you do? Which is most correct? 1. Explain to her that the serum free light chain results indicate myeloma 2. Explain to her it was inappropriate for her to be on oxycodone and in view of the normal IgG, she doesn t need to be followed up for a couple of years. 3. Undertake a urinary Bence Jones Protein as they are more reliable that serum free light chains. 4. Refer her to exclude a plasmacytoma
19 Int. Myeloma Working Group BJH, 2003; 121: Monoclonal Gammopathy of undetermined significance strict definition. 3% over the age of 50 yrs., 5% over the age of 70 yrs. No evidence of other B-cell disorders or amyloidosis M-protein < 30g/l and <10% plasma cells on BM No myeloma-related symptoms/organ damage
20 Rate of progression of MGUS Progression at 10 yrs. 9% 20 yrs. 20% 25 yrs. 30% 1% progression per year, for patients who have not died of other causes R L Spearing
21 But can we predict which will progress i.e. which need closer monitoring? Just based on the lab results, what would this mans chance be of progressing at 20 years 1. 5% % 3. 40% 4. 60% 5. 80%
22 How do you predict which patients will progress? 3 important factors help predict: 1. Type of paraprotein- If IgA more likely to progress than IgG (remember if a IgM paraprotein progresses - usually associated with a low grade lymphoma, not myeloma) 2. If serum free light chain RATIO is abnormal, more likely to progress 3. If high level of paraprotein i.e. >15g/L. However many labs don t quantify the paraprotein
23 Risk-Stratification Model to Predict Progression of MGUS to Myeloma Risk Group Low Risk Monoclonal protein <15 g/l, IgG type, normal FLC ratio Low-Intermediate Risk Any one factor abnormal High-Intermediate Risk Any two factors abnormal High-Risk (5% of group) All three factors abnormal Absolute Risk of Progression at 20 years 5% 21% 37% 58% Rajkumar Blood, 2005;106:
24 However this woman didn t have MGUS because she had bone pain Seen 7 months later, significant ongoing PAIN in thoracic region. Ig G now 18 g/l ( had been 12g/L, 7 months previously i.e. RATE of increase is important). Kappa serum free light chain=27 mg/l ( ) Lambda free light chain = 10 mg/l ( ) with a kappa/lambda ratio of 2.73 ( ) MRI showed multiple lytic lesions in the spine and the bone marrow 18% plasma cells i.e. myeloma
25 Recent move to treat myeloma earlier Previously international guidelines= needed raised calcium /renal impairment/anaemia/bone pain (CRAB) before treating Now - low dose CTs performed on MGUS with high risk features Indication to treat = 2 lesions on MRI/CT scan; SFLC ration of >100 plasma cell >60% even without end organ damage
26 Lessons from this case Pain out of proportion to the injury Bence Jones protein is an obsolete test Ratio of the 2 light chains is what to look as both will go up in infection Rate of rise of the paraprotein or SFLC is important as well as total level
27 A sad case 51 yr. old woman screening for a weight loss trial. Kappa paraprotein -low total IgG of 7g/L and an initially N SFLC ratio, though by the next year had become weakly positive mg/L ( ) Asymptomatic 5% risk of progressing to MM, lymphoma or other B Cell neoplasm at 20 years However, SFLC ratio and Ig level then stable for next 7 years and so FU extended to 6-12 monthly
28 SFCL Ratio Dec 2013 increased from 3.39 to 4.96 ( ) Ig G unchanged Letter from locum is that increase significant? I am quite happy with her present IgG level and her SFLC ratio No absolute cut off for when a serum free light chain may be of significance but usually it is at least 100. Thank you for continuing to monitor her with 6 to 12 monthly serum free light chains, immunoglobulins, calcium, albumin, creatinine and full blood count and questions about weight loss, night sweats and bone pain. Examination should include looking for palpable liver spleen and lymph nodes.
29 What I didn t say was the RATE of rise = Important Oct 2014 SCLF =20.2 up from 4.9 ten months earlier (N= ) Jan 2015 developed pain visited new locum x9 times. Referred to musculoskeletal specialist in July who repeated the SFLC ratio now Bone marrow 90% plasma cells. Pain very difficult to control.
30 Myeloma update Newer drugs such as S/C weekly bortezomib/weekly 40mg dexamethasone plus cyclophosphamide followed by stem cell transplant for <70year olds = median survival of 7-9 years Bortezomib/dexa/cyclo without transplant reasonably tolerated up into 70s, some 80s. Dose of weekly dexa 20mg/wk. NB: Significant bone pain even with a low level paraprotein can be a plasmacytoma RATE of RISE of paraprotein/sflc important - Not absolute figure.
31 Chronic lymphocytosis GP referral- Written advice only Semi-urgent - 24-Jul :26 chronic lymphocytosis.?monitor yearly or needs to be seen blood test shows lymphocytosis recommend marker studies no wt. loss no recurrent infections no night sweats. wt. 107 no lymphadenopathy neck axilla groin abdo snt. no hepatosplenomegaly. P lymphocyte marker studies.
32 Mild Lymphocytosis- When should one recheck it? Nothing hard and fast needs to be put into clinical context?viral symptoms/wt. loss/recurrent infections/night sweats/lymphadenopathy neck axilla groin/hepatosplenomegaly This man had only had 1 previous blood test - Lymphocytes had been 6 x10 9 /L in 2013.
33 Request a film on the FU film If no symptoms suggest do FU film at 6 weeks but instruct to return sooner if symptoms. Film may show large activated lymphocytes as per a viral infection May show smear cells occur in Chronic Lymphocytic Leukaemia but are non-specific The lab may see other significant abnormalities
34 What do you not want to miss? Common things are common most mild lymphocytosis=either viral or early CLL However diagnoses not to miss e.g. a Mantle Cell Lymphoma Therefore need surface markers (SM) -Can ask for surface markers please if lymphocytes still raised Costs around $400 so do it once only do NOT need repeating
35 Frequent result- Clonal B-Cell Lymphocytosis The phenotype is that of Chronic Lymphocytic Leukaemia. However, the clone of abnormal cells is less than 5x 10 9 /L, so unless there is a palpable spleen, or lymph nodes, it doesn t meet the full clinical criteria of Chronic Lymphocytic Leukaemia and would fall in to the category of Clonal B-Cell Lymphocytosis. Unless there are clinical features to indicate otherwise, only infrequent follow up is indicated. (Monoclonal B-Cell Lymphocytosis. Rawstron et al, NEJM 2008;359;6). See also Health Pathways
36 Clonal lymphocytosis of unknown significance (CLUS) Low level, subclinical "disease" <5 x /l with classical Chronic Lymphocytic Leukaemia markers on immunophenotyping Present in 3.5% of normal adults - up to 8% of individuals over the age of 70 13% have 1st degree relatives with CLL Analogous to MGUS- unclear as to what % will progress: Appears to lead to mild disease
37 Again clinical history and examination all important MUST ask about night sweats/wt. loss/infections at EACH visit and tell them to report these MUST look for LN/L/S at EACH visit If no red flags, yearly or even 2 yearly follow up is appropriate No need to repeat SM when the increase in lymphocytes makes the diagnosis officially CLL
38 CLL In CLL, the height of the white count unimportant Indication to refer: Hb or platelet count dropping out of the normal range Development of splenomegaly Significant LNs
39 Summary of take home points Have a simple schema for anaemais Importance of reticulocyte count and blood film in sorting out anaemias If a patient has a even a low level of paraprotein with bone pain, think of plasmacytoma The RATE of change for immunoglobulins/sflc is important Bence Jones Protein = obsolete In a patient with a CLUS you don t need to repeat the surface markers when the count increases
40
Southern Derbyshire Shared Care Pathology Guidelines. MGUS (Monoclonal Gammopathy of Undetermined Significance)
Southern Derbyshire Shared Care Pathology Guidelines MGUS (Monoclonal Gammopathy of Undetermined Significance) Purpose of guideline This guideline provides information about the risk stratification of
More informationRory McCulloch. Specialty Trainee Haematology Royal Devon & Exeter Hospital
Rory McCulloch Specialty Trainee Haematology Royal Devon & Exeter Hospital Anaemia 1 Haematological disorders Anaemia 2 Non-haematological disorders Substrates: Iron, folate, vitamin B12 Red cell mass
More informationMichael Joffe ST6 Haematology SpR
Michael Joffe ST6 Haematology SpR Mrs SB 71 year old female on AMU Telephone referral to haematology by medicine with Hb 102 MCV 89, normal B12, Folate, Ferritin. PMH DM General decline over several weeks
More informationGP Referral Guidelines. for. South Wales Cancer Network. Document Control Sheet. Specialty/Project Haematological Site Specific Group
GP Referral Guidelines for South Wales Cancer Network Document Control Sheet Organisation South Wales Cancer Network Specialty/Project Haematological Site Specific Group Document Title GP Referral Guidelines
More informationHematology 101. Rachid Baz, M.D. 5/16/2014
Hematology 101 Rachid Baz, M.D. 5/16/2014 Florida 101 Epidemiology Estimated prevalence 8,000 individuals in U.S (compare with 80,000 MM patients) Annual age adjusted incidence 3-8/million-year 1 More
More informationPlasma cell myeloma (multiple myeloma)
Plasma cell myeloma (multiple myeloma) Common lymphoid neoplasm, present at old age (70 years average) Remember: plasma cells are terminally differentiated B-lymphocytes that produces antibodies. B-cells
More informationM-Protien, what to do next? Ismail A Sharif MD, FRCPc Internal Medicine Day 22 nd April 2016
+ M-Protien, what to do next? Ismail A Sharif MD, FRCPc Internal Medicine Day 22 nd April 2016 + Disclosures Advisory Boards: AMGEN, Lundbeck, NOVARTIS + Subtypes of Plasma Cell Disorders Increased Plasma
More informationHaematological Cancer Suspected (Adults & Children)
Haematological Cancer Suspected (Adults & Children) Link to NICE guidelines: https://www.nice.org.uk/guidance/ng47 Patient of any age presents with symptoms of possible haematological cancer If 60 years
More informationGP CME. James Liang Consultant Haematologist. Created by: Date:
GP CME James Liang Consultant Haematologist Date: Created by: Scenario 52 year old European male Fit and well Brother recently diagnosed with diabetes PMHx Nil Social Hx Ex-smoker stopped 5 years ago (20
More informationWestern Health Specialist Clinics Access & Referral Guidelines
Haematology Specialist Clinics at Western Health: Western Health runs MBS funded Specialist Clinics on a Wednesday and Thursday afternoon at its Sunshine Hospital site for patients who require assessment
More informationBlood Cancers in the Community
Over to you, mate Blood Cancers in the Community National Rural Health Conference NZ Rural General Practice Network April 7, 2018 Brian Grainger Haematology Registrar Auckland Acknowledgements Dr James
More informationCandidates must answer ALL questions
Time allowed: Three hours. Part 1 examination Haematology: First paper Tuesday 22 March 2016 Candidates must answer ALL questions Question 1: General Haematology A 16 year old non-european is referred
More information2013 AAIM Pathology Workshop
2013 AAIM Pathology Workshop John Schmieg, M.D., Ph.D. None Disclosures 1 Pathology Workshop Objectives Define the general philosophy of reviewing pathology reports Review the various components of Bone
More informationTYPE 1 GAUCHER DISEASE PRESENTING AS PERSISTENT THROMBOCYTOPENIA, ASSOCIATED FACTOR XI DEFICIENCY & EMERGENT MYELOMA
TYPE 1 GAUCHER DISEASE PRESENTING AS PERSISTENT THROMBOCYTOPENIA, ASSOCIATED FACTOR XI DEFICIENCY & EMERGENT MYELOMA Trish Hyland, Medical Scientist, Department of Haematology, Cork University Hospital
More informationCriteria for Disease Assessment Joan Bladé
Criteria for Disease Assessment Joan Bladé Unidad de Amiloidosis y Mieloma Servicio de Hematología Hospital Clínic de Barcelona COMy Meeting, París, May 4th, 2018 Response Evaluation EBMT, 1998 - CR and
More informationFBC interpretation. Dr. Gergely Varga
FBC interpretation Dr. Gergely Varga #1 71 Y/O female, c/o weakness Test Undertaken : FBC (FBC) Sample Type: Whole Blood [ - 26.09.11 14:59] Hb 7.3 g/dl* 12.0-15.5 RBC 3.5 10^12/l * 3.80-5.60 Hct 0.24
More informationLec-14 د.خالد نافع. Medicine. Multiple Myeloma
Fifth stage Lec-14 د.خالد نافع Medicine 24/4/2016 Multiple Myeloma Plasma cell myeloma Variants Non - secretory myeloma Indolent myeloma Smouldering myeloma Plasma cell leukaemia Plasmacytoma - Solitary
More informationMultiple Myeloma 101: Understanding Your Labs
Multiple Myeloma 101: Understanding Your Labs Tim Wassenaar MD MS Hematologist, Director of Clinical Trials UW Cancer Center at ProHealth Care None Disclosures Outline Define hematopoiesis WBCs, RBCs,
More informationSerum free light chain (SFLC) assays. Dr Sarah Sasson SydPath Registrar
Serum free light chain (SFLC) assays Dr Sarah Sasson SydPath Registrar Introduction to SFLC Plasma cell dyscrasias such as monoclonal gammopathy of uncertain significance (MGUS) smouldering/asymptomatic
More informationWHO Classification. B-cell chronic lymphocytic leukemia/small T-cell granular lymphocytic leukemia
Blood Malignancies-II Prof. Dr. Herman Hariman, a Ph.D, SpPK (KH). Prof. Dr. Adikoesoema Aman, SpPK (KH) Dept. of Clinical Pathology, School of Medicine, University of North Sumatra WHO classification
More informationCommon Haematological Problems in Primary Care
23 rd March 2019 GP Hot Topics In Primary Care Common Haematological Problems in Primary Care Dr Samar Kulkarni Consultant Haematologist-Oncologist and The Christie Private Care Manchester, UK. Haematology?
More informationCase #1. Robert J. Glinert, M.D. David C. Fisher, M.D. Dana Farber Cancer Institute
Case #1 Robert J. Glinert, M.D. David C. Fisher, M.D. Dana Farber Cancer Institute Patient History Part I 76 year-old man 1997 diagnosed with MGUS (biclonal) during evaluation of (self-limited) anemia.
More informationBurkitt lymphoma. Sporadic Endemic in Africa associated with EBV Translocations involving MYC gene on chromosome 8
Heme 8 Burkitt lymphoma Sporadic Endemic in Africa associated with EBV Translocations involving MYC gene on chromosome 8 Most common is t(8;14) Believed to be the fastest growing tumor in humans!!!! Morphology
More informationMr Matthew Eby. Dr Humphrey Pullon
Dr Humphrey Pullon Haematologist Hamilton Mr Matthew Eby Senior Support Services Coordinator Leukaemia & Blood Cancer Foundation New Zealand Hamilton 16:30-17:25 WS #64: Managing Haemopoetic Disease in
More informationThe ABCs of Waldenström s Macroglobulinemia (WM)
The ABCs of Waldenström s Macroglobulinemia (WM) Jeffrey V. Matous MD Colorado Blood Cancer Institute IWMF Ed Forum May 2017 Objectives Describe the roots underneath WM Review incidence, possible risk
More informationMultiple myeloma Biological & Clinical Aspects Isabelle Vande Broek, MD, PhD
Multiple myeloma Biological & Clinical Aspects Isabelle Vande Broek, MD, PhD Department of Oncology & Hematology AZ Nikolaas Iridium Kanker Netwerk Introduction Multiple myeloma = Kahler s disease Dr.
More informationKing s Health Partners Haematology Institute and Network GP Referral Guide, Adult Haematology
King s Health Partners Haematology Institute and Network GP Referral Guide, Adult Haematology 1 Version control: There are two controlled versions of this document, one for GSTT and one for KCH. While
More informationIf unqualified, Complete remission is considered to be Haematological complete remission
Scroll right to see the database codes for Disease status and Response Diagnosis it refers to Disease status or response to treatment AML ALL CML CLL MDS or MD/MPN or acute leukaemia secondary to previous
More informationIf unqualified, Complete remission is considered to be Haematological complete remission
Scroll right to see the database codes for Disease status and Response Diagnosis it refers to Disease status or response to treatment AML ALL CML CLL MDS or MD/MPN or acute leukaemia secondary to previous
More informationKing s Health Partners Haematology Institute and Network GP Referral Guide, Adult Haematology
King s Health Partners Haematology Institute and Network GP Referral Guide, Adult Haematology For two week wait pathway, please continue to use existing documentation/pathways. Telephone advice and guidance
More informationMorphology Case Study. Presented by Niamh O Donnell, BSc, MSc. Medical Scientist Haematology Laboratory Cork University Hospital
Morphology Case Study Presented by Niamh O Donnell, BSc, MSc. Medical Scientist Haematology Laboratory Cork University Hospital 41 year old male presented to GP for routine check-up in May 2011. FBC Results:
More informationHematology Case Conference 8/5/03
Hematology Case Conference 8/5/03 Bone Marrow Case Patient: Emmxxx Lylexxx 74 year old AA female S/P craniotomy for SDH. Pt has Hx of HTN, DM, Crohn s disease, (R) nephrectomy. Bone marrow for abnormal
More informationSuspecting Tumors, or Could it be cancer?
Suspecting Tumors, or Could it be cancer? Donna E. Reece, M.D. Princess Margaret Cancer Centre University Health Network Toronto, ON CANADA 07 February 2018 Background Low back pain is common However,
More informationTESTS AND INVESTIGATIONS FOR MULTIPLE MYELOMA A guide for patients and caregivers
TESTS AND INVESTIGATIONS FOR MULTIPLE MYELOMA A guide for patients and caregivers Developed by the Myeloma Special Practice Network (M-SPN) of the Haematology Society of Australia and New Zealand (HSANZ)
More informationThe patient had a mild splenomegaly but no obvious lymph node enlargement. The consensus phenotype obtained from part one of the exercise was:
Case History An 86 year old male was admitted to hospital with chest infection. Haematological examination subsequently revealed the following: Hb- 11.0 g/dl; WBC- 67.1 x 10^9/l; PLT- 99 x10^9/l; RBC-
More informationSmoldering Multiple Myeloma. A Case Study
Smoldering Multiple Myeloma A Case Study Case Presentation 53-Year-Old Male Patient presented for a routine exam No prior history of disease or family history of fhematologic disorders d or malignancies,
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL RESPONSE ASSESSMENT MYELOMA CHAPTER 11C REVISED: SEPTEMBER 2016
MYELOMA Quantitative Markers-Myeloma Assessment Quantitative markers are biochemicals that are recorded in tests on body fluids such as serum and urine. Applicable Disease Sites The myeloma disease site
More informationOsteosclerotic Myeloma (POEMS Syndrome)
Osteosclerotic Myeloma (POEMS Syndrome) Osteosclerotic Myeloma (POEMS Syndrome) Synonyms Crow-Fukase syndrome Multicentric Castleman disease Takatsuki syndrome Acronym coined by Bardwick POEMS Scheinker,
More informationMultiple Myeloma: diagnosis and prognostic factors. N Meuleman May 2015
Multiple Myeloma: diagnosis and prognostic factors N Meuleman May 2015 Diagnosis Diagnostic assessment of myeloma: what should we know? Is it really a myeloma? Is there a need for treatment? What is the
More informationProblem Based Learning
Problem Based Learning 2 Dania Qarqash&OmaymaHassanin Enas Ajarma Dr.Hikmat Abdel-Razeq Clinical hematology is divided into four subjects : 1- Benign hematology Anemia Benign WBC disorders Bone marrow
More informationHaematology dilemma s to refer or not to refer?
Haematology dilemma s to refer or not to refer? NWL Pathology GP Study Day Dr Fatts Chowdhury Consultant Haematologist in Transfusion Medicine NHS Blood and Transplant Senior Honorary Clinical Lecturer
More informationBortezomib (Velcade)
Bortezomib (Velcade) Policy Number: Original Effective Date: MM.04.003 03/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 06/01/2015 Section: Prescription Drugs Place(s)
More informationImportancia del laboratorio en el seguimiento clínico de pacientes con mieloma múltiple
Importancia del laboratorio en el seguimiento clínico de pacientes con mieloma múltiple Joan Bladé Unidad de Amiloidosis y Mieloma Servicio de Hematología Hospital Clínic de Barcelona Málaga, 16 de noviembre
More informationLymphoma/CLL 101: Know your Subtype. Dr. David Macdonald Hematologist, The Ottawa Hospital
Lymphoma/CLL 101: Know your Subtype Dr. David Macdonald Hematologist, The Ottawa Hospital Function of the Lymph System Lymph Node Lymphocytes B-cells develop in the bone marrow and influence the immune
More informationComplete Blood Count in Primary Care
QUIZ FEEDBACK Complete Blood Count in Primary Care bpac nz better medicine GP Review Panel: Dr Janine Bailey, Motueka Dr Susie Lawless, Dunedin Dr Randall Sturm, Auckland Dr Neil Whittaker, Nelson Specialist
More informationQ&A Session Collecting Cancer Data: Hematopoietic and Lymphoid Neoplasms Thursday, November 6, 2014
Q&A Session Collecting Cancer Data: Hematopoietic and Lymphoid Neoplasms Thursday, November 6, 2014 Q: If polycythemia ruba vera (PRV) or essential thrombocythemia (ET) is diagnosed by peripheral smear,
More informationLeukocytosis - Some Learning Points
Leukocytosis - Some Learning Points Koh Liang Piu Department of Hematology-Oncology National University Cancer Institute National University Health System Objectives of this talk: 1. To provide some useful
More informationNICE guideline on Suspected cancer: recognition and referral (2015) Education package for GPs and Nurse Practitioners Case scenarios
NICE guideline on Suspected cancer: recognition and referral (2015) Education package for GPs and Nurse Practitioners Case scenarios How to use the case scenarios The case scenarios can be used in a training
More informationChronic Lymphocytic Leukemia (CLL)
Page 1 of 10 PATIENT EDUCATION Chronic Lymphocytic Leukemia (CLL) Introduction Chronic lymphocytic leukemia (CLL) is a type of cancer of the lymphocytes (a kind of white blood cell). It is also referred
More informationFBC CASES Vernon Louw Clinical Haematology 2010
FBC CASES Vernon Louw Clinical Haematology 2010 FOR EACH OF THE FOLLOWING PATIENTS, SELECT THE MOST LIKELY FINDING FROM THE ANALYSIS OF THE PERIPHERAL BLOOD. A patient with infectious mononucleosis. A
More informationManagement of Multiple Myeloma
Management of Multiple Myeloma Damian J. Green, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance New Treatment Options Have Improved OS in MM Kumar SK, et al. Blood. 2008;111:2516-2520.
More informationPOEMS syndrome. This Infosheet explains what POEMS syndrome is, how it is diagnosed and how it is treated and managed.
POEMS syndrome This Infosheet explains what POEMS syndrome is, how it is diagnosed and how it is treated and managed. What is POEMS syndrome? POEMS syndrome is a rare type of plasma cell disorder that
More informationSmoldering Myeloma: Leave them alone!
Smoldering Myeloma: Leave them alone! David H. Vesole, MD, PhD Co-Director, Myeloma Division Director, Myeloma Research John Theurer Cancer Center Hackensack University Medical Center Prevalence 1960 2002
More informationMYE FORMS REVEALED RESPONSE CODES OBJECTIVES. Stringent Complete Response (scr) Complete Response (CR) I have no conflicts of interest to disclose
I have no conflicts of interest to disclose MYE FORMS REVEALED Janet Brunner, PA-C CIBMTR MKE New10_1.ppt OBJECTIVES 1) Be able to describe the criteria required for each myeloma response code 2) Be able
More informationForms Revision: Myeloma Changes
Sharing knowledge. Sharing hope. Forms Revision: Myeloma Changes J. Brunner, PA-C and A. Dispenzieri, MD February 2013 Disclosures Janet Brunner, PA-C I have no relevant conflicts of interest to disclose.
More informationCytopaenias in HIV. Dr Maresce Bizaare Specialist Physician Clinical Haematology Fellow IALCH
Cytopaenias in HIV Dr Maresce Bizaare Specialist Physician Clinical Haematology Fellow IALCH Introduction Cytopaenias in HIV are common Anaemias multifactorial causes Thrombocytopaenias may be the first
More informationMultiple Myeloma Early Detection, Diagnosis, and Staging
Multiple Myeloma Early Detection, Diagnosis, and Staging Detection and Diagnosis Catching cancer early often allows for more treatment options. Some early cancers may have signs and symptoms that can be
More informationShould we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain
Should we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain Should we treat some patients with Stage I MM? Len-dex is a promising and atractive option
More informationBlood Cancer: Chronic Myelogenous Leukaemia
Published on: 30 May 2017 Blood Cancer: Chronic Myelogenous Leukaemia What Is Cancer? The body is made up of cells that grow and die in a controlled way. Sometimes, cells keep dividing and growing without
More informationPart 1 examination. Haematology: First paper. Tuesday 20 March Candidates must answer all questions. Each question is worth a total of 25 marks.
Part 1 examination Haematology: First paper Tuesday 20 March 2018 Candidates must answer all questions. Each question is worth a total of 25 marks. Time allowed: 3 hours Question 1: General Haematology
More informationMonoclonal Gammopathy with Systemic Amyloidosis: An Evaluation of Diagnostic Elements
: 51-55 Monoclonal Gammopathy with Systemic Amyloidosis: An Evaluation of Diagnostic Elements 1 C. T Subashini*, 1 E. George & 2 U Nor Aini 1 Department of Pathology, Faculty of Medicine and Health Sciences,
More informationGP Education Haematology laboratory abnormalities- when to refer? Priyanka Mehta Consultant Haematologist UH Bristol NHS Trust
GP Education Haematology laboratory abnormalities- when to refer? Priyanka Mehta Consultant Haematologist UH Bristol NHS Trust Topics for discussion Abnormal FBCs Lymphocytosis high and low platelets cytopenias
More informationHematology: Challenging Cases with Your Participation COPYRIGHT
Hematology: Challenging Cases with Your Participation Reed E. Drews, MD Beth Israel Deaconess Medical Center Harvard Medical School Boston, MA Question 1 Question 1 64-year-old man is evaluated during
More informationVelcade (bortezomib)
Velcade (bortezomib) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 03/09/2004 Current Effective Date: 05/01/2017 POLICY A. INDICATIONS The indications below
More informationBorderline cytopenias. Dr Taku Sugai Consultant Haematologist
Borderline cytopenias Dr Taku Sugai Consultant Haematologist Borderline cytopenias Neutropenia Thrombocytopenia Anaemia with normal haematinics Two recent cases of cytopenias Neutropenia ANC of more than
More informationManagement Update: Multiple Myeloma. Presented by Prof. Dr. Khan Abul Kalam Azad Professor of Medicine Dhaka Medical College
Management Update: Multiple Myeloma Presented by Prof. Dr. Khan Abul Kalam Azad Professor of Medicine Dhaka Medical College Introduction Multiple myeloma - clonal plasma cell neoplasm Monoclonal antibody
More informationMultiple myeloma: from diagnosis to treatment
Diagnostic challenges Renee Eslick Dipti Talaulikar Multiple : from diagnosis to treatment Background Multiple is characterised by the proliferation of malignant plasma cells within the bone marrow, which
More informationHEFT Pathology Guideline. GP Investigation and Referral Pathways for leucocyte, platelet disturbances and polycythaemia
HEFT Pathology Guideline GP Investigation and Referral Pathways for leucocyte, platelet disturbances and polycythaemia Produced by: Dr Charalampos Kartsios (Consultant Haematologist) and Muhammad Javed
More informationSerum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance S. Vincent
More informationIBRUTINIB (IMBRUVICA ) for Chronic Lymphocytic Leukaemia. and Mantel Cell Lymphoma
DRUG ADMINISTRATION SCHEDULE Indication Cycle Length Drug Daily Dose Route Schedule Chronic Lymphocytic Leukaemia Continuous Ibrutinib 420mg (three capsules) Oral ONCE daily Mantel Cell Lymphoma Continuous
More informationAlister Jones Patient Blood Management Practitioner NHS Blood and Transplant
Alister Jones Patient Blood Management Practitioner NHS Blood and Transplant All medical RCC transfusions (but only 1 in 3 haematology or oncology cases) in 3 x one week periods Medical specialties include:
More informationInterpreting Blood Tests Part 1. Dr Andrew Smith
Interpreting Blood Tests Part 1 Dr Andrew Smith Outline Part 1 (This Week) Introduction Which Tube!?! FBCs U+Es Part 2 (Next Week): More Electrolytes LFTs Clotting Extras Introduction Bloods are a core
More informationCLL & SLL: Current Management & Treatment. Dr. Isabelle Bence-Bruckler
CLL & SLL: Current Management & Treatment Dr. Isabelle Bence-Bruckler Chronic Lymphocytic Leukemia Prolonged clinical course Chronic A particular type of white blood cell B lymphocyte Lymphocytic Cancer
More informationCase Workshop of Society for Hematopathology and European Association for Haematopathology
Case 148 2007 Workshop of Society for Hematopathology and European Association for Haematopathology Robert P Hasserjian Department of Pathology Massachusetts General Hospital Boston, MA Clinical history
More informationVelcade (bortezomib)
Velcade (bortezomib) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective Date: 03/09/2004 Current Effective Date: 03/01/2018 POLICY A. INDICATIONS The indications below
More informationExpanding Spectrum of Diseases Associated with Plasma Cell Dyscrasias
Expanding Spectrum of Diseases Associated with Plasma Cell Dyscrasias Eva Honsova Institute for Clinical and Experimental Medicine Prague, Czech Republic eva.honsova@ikem.cz Plasma cell dyscrasias Plasma
More informationHaematology for GP's
Haematology for GP's Dr Christina Zouvelou Consultant Haematologist SOUTHEND UNIVERSITY HOSPITALS NHS FT SPIRE WELLESLEY HOSPITAL Time to Learn, 03/07/2018 Anaemia Careful history (duration, symptoms,
More informationCitation for published version (APA): Hovenga, S. (2007). Clinical and biological aspects of Multiple Myeloma s.n.
University of Groningen Clinical and biological aspects of Multiple Myeloma Hovenga, Sjoerd IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
More informationWHAT IS YOUR DIAGNOSIS?
WHAT IS YOUR DIAGNOSIS? A 12 year old, female neutered domestic shorthaired cat was presented to the R(D)SVS Feline Clinic with a 6 week history of polydipsia and polyuria, which was not quantified. The
More informationPathology #07. Hussein Al-Sa di. Dr. Sohaib Al-Khatib. Mature B-Cell Neoplasm. 0 P a g e
Pathology #07 Mature B-Cell Neoplasm Hussein Al-Sa di Dr. Sohaib Al-Khatib 0 P a g e Thursday 18/2/2016 Our lecture today (with the next 2 lectures) will be about lymphoid tumors This is a little bit long
More informationMyeloma. A guide for patients and families leukaemia.org.au
Myeloma A guide for patients and families 1800 620 420 leukaemia.org.au Contents Acknowledgments 4 Introduction 5 The Leukaemia Foundation 6 Blood cancers 10 What is myeloma? 16 Who gets myeloma? 20 How
More informationLaboratory Examination
Todd Zimmerman, M.D. 64 year old African American male presents to establish care with PCG. Meds: Norvasc 5 mg daily PMHx: HTN x 20 years, poorly controlled SHx: No tobacco, illicit; rare EtOH ROS: Negative
More informationDr Prashant Tembhare
Dr Prashant Tembhare docprt@gmail.com FCM very powerful technology in Identification and characterization of neoplastic plasma cells as it allows - simultaneous assessment of multiple antigens large numbers
More informationPLASMA CELL NEOPLASIA. Michael Miller, MD & Ajaz Shawl, MD
PLASMA CELL NEOPLASIA Michael Miller, MD & Ajaz Shawl, MD Plasma Cell Neoplasia Board Questions Case Presentation Introduction Epidemiology Presentation Diagnosis Laboratory Tests Imaging Differentials
More informationInvestigation and Management of Chronic Lymphocytic Leukemia. James Johnston
Investigation and Management of Chronic Lymphocytic Leukemia James Johnston Site Specific Clinics CLL Clinic (787-4454) Erin Elphee BN James Johnston Rajat Kumar Matt Seftel (transplant) Myeloma Clinic
More informationThe Lymphomas. An overview..
The Lymphomas An overview.. Peter Anglin MD, FRCPC, MBA Stronach Regional Cancer Centre Newmarket, ON The lymphomas are an important part of the history of medicine 1666 Magpighi publishes first recorded
More information2016: Plasma Cell Disorders Pre-HCT Data
2016: Plasma Cell Disorders Pre-HCT Data Registry Use Only Sequence Number: Date Received: Key Fields CIBMTR Center Number: Date of HCT for which this form is being completed: / / YYYY MM DD HCT type (check
More informationInstructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113)
Instructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the CLL Post-HSCT Data Form. E-mail
More informationPlasma Cell Disorders (PCD) Pre-HCT Data
Plasma Cell Disorders (PCD) Pre-HCT Data Registry Use Only Sequence Number: Date Received: CIBMTR Center Number: CIBMTR Recipient ID: Date of HCT for which this form is being completed: HCT type: (check
More informationDiseases Of The Blood
Diseases Of The Blood DR. Associate Professor Of Pathology Faculty Of Medicine Ain Shams University Red Blood Cells and Anemia RBC=4-6 million/mm 2 Hb=12-18 g/dl Oxygen Carrying Molecule Hemoglobin Tetramer:
More informationDr Kirsten Herbert. Dr Melita Kenealy. MBBS(Hons) FRCPA FRACP. Common Blood Tests
Common Blood Tests Your Haematologist may order numerous blood and urine tests to help diagse or manage your condition. Listed below are some of the more common tests that can be ordered in a haematology
More informationAnemia. A case-based approach. David B. Sykes, MD, PhD Hematology, MGH Cancer Center June 8, 2017
Anemia A case-based approach David B. Sykes, MD, PhD Hematology, MGH Cancer Center June 8, 2017 Recognizing trends Learning Objectives MCV, RDW, Ferritin, LDH, Reticulocytes Managing complex patients 1.
More informationJo Abraham MD Division of Nephrology University of Utah
Jo Abraham MD Division of Nephrology University of Utah 68 year old male presented 3 weeks ago with a 3 month history of increasing fatigue He reported a 1 week history of increasing dyspnea with a productive
More informationWaldenstrom s Macroglobulinemia
Waldenstrom s Macroglobulinemia : Introduction Waldenstrom s macroglobulinemia (WM) is a lymphoma, or cancer of the lymphatic system. It occurs in a type of white blood cell called a B-lymphocyte or B-cell,
More informationA.M.W. van Marion. H.M. Lokhorst. N.W.C.J. van de Donk. J.G. van den Tweel. Histopathology 2002, 41 (suppl 2):77-92 (modified)
chapter 4 The significance of monoclonal plasma cells in the bone marrow biopsies of patients with multiple myeloma following allogeneic or autologous stem cell transplantation A.M.W. van Marion H.M. Lokhorst
More informationSUPPLEMENTARY APPENDIX
SUPPLEMENTARY APPENDIX The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network Niels W.C.J.
More informationTest Utilization: Chronic Lymphocytic Leukemia
Test Utilization: Chronic Lymphocytic Leukemia Initial Evaluation Diagnostic Criteria Selection of Tests for Prognosis Response to Therapy Challenges Assessment for persistent disease Paul J. Kurtin, M.D.
More informationSerum Free Light Chain Assay
Serum Free Light Chain Assay This Infosheet explains what light chains are, what the Serum Free Light Chain Assay is, and why it is used in AL amyloidosis. In AL amyloidosis, abnormal plasma cells in the
More informationI Need Treatment First-Line WM Treatments & Side Effects IWMF Educational Forum Grapevine, TX 5/1/2015
I Need Treatment First-Line WM Treatments & Side Effects IWMF Educational Forum Grapevine, TX 5/1/2015 Larry Anderson, MD, PhD Plasma Cell Disorder and Stem Cell Transplant Specialist UT Southwestern Medical
More informationSmouldering Myeloma: to treat or not to treat?
Smouldering Myeloma: to treat or not to treat? Massimo Offidani Clinica di Ematologia Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona Definitions and epidemiology 3000-5000 new SMM/year in
More information